Main description:

Published in the series Headache, endorsed by the European Headache Federation, this is the first book on the novel synthetic treatment of migraine with ditans (lasmiditan) and gepants (atogepant, ubrogepant, rimegepant, vazegepant). These drugs will provide additional options for people with migraine put at risk of side effects by other medications or with unsatisfactory response to previous drugs. There is now a sufficient amount of literature published to interest a wide multidisciplinary readership (general physicians, general neurologists, clinical psychologists, neurologists in training, and medical students) facing every day this burdensome disorder in their clinical practice. The book aims therefore at offering an overview of these new drugs for both acute and prophylactic treatments of migraine, covering studies on clinical evidence, tolerability, and the different stages of clinical development.

Contents:

PrefaceForeword1. Novel Pharmacological Targets of Migraine: An Overview 2. Molecular and cellular mechanisms of CGRP antagonists3. Atogepant4. Ubrogepant 5. Rimegepant6. Zavegepant7. Molecular mechanisms of 5-HT1F receptor agonists8. Lasmitidan9. Update on old and current targets for anti-migraine therapies